GlassScriptPhysician profile
Annalissa Kammeyer Smith
NPI 1710515887
$2,476.51
in general payments reported to CMS, 2019-2025
27 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $644 · 2023: $523 · 2024: $859 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $593.95 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $283.56 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.22 | 2022-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $164.45 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $136.83 | 2022 | |
| Axsome Therapeutics, INC. | $103.14 | 2023-2025 | Auvelity |
| Amgen INC. | $102.69 | 2024-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $100.12 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $96.81 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.69 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $84.76 | 2023-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.54 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $60.50 | 2023-2024 | Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $50.17 | 2023-2024 | Trintellix |
| Sumitomo Pharma America, INC. | $36.19 | 2024 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.17 | 2023-2024 | Gardasil 9, Varivax, Capvaxive |
| Xeris Pharmaceuticals, INC. | $33.10 | 2024-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $31.75 | 2024 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.95 | 2023-2024 | Xifaxan |
| Inspire Medical Systems, INC. | $27.69 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $27.01 | 2024 | Voquezna |
| Astellas Pharma US INC | $23.19 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $18.03 | 2023 | Nucala |
| Shield Therapeutics INC | $16.58 | 2024 | |
| Neurocrine Biosciences, INC. | $15.29 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.72 | 2022 | |
| Mylan Specialty L.P. | $14.41 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annalissa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.